Cancer specific gene MH15

• US 7,507,532 B2
• Filed: 03/07/2005
• Issued: 03/24/2009
• Est. Priority Date: 03/08/2004
• Status: Expired due to Fees

• Current Assignee: Medigen Biotechnology Corp.
• Original Assignee: Medigen Biotechnology Corp.
• Inventors: Hsu, Chih-Ping, Chang, Stanley, Chen, Kuo-Yen, Kuo, Wei-Ying, Li, Ning-Yi, Ho, Pei-Hsun, Chang, Hsun-Lang
• Primary Examiner(s): Aeder; Sean E
• Application Number:
  US11/074,129
• Publication Number:
  US 20060068411A1
• Time in Patent Office: 1,478 Days
• Field of Search: 435/6
• US Class Current: 435/6.14
• CPC Class Codes: C07K 16/30 from tumour cells
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 33/5748 involving oncogenic proteins

Abstract

MH15 (Hn1L) is identified as an oncogene. Methods and compositions for detecting and diagnosing cancer in patients are provided, by determining the level of MH15 expression in biological samples. Also provided are methods for screening for inhibitors and moderators of MH15 expression and activity, as well as compositions comprising compounds and molecules that inhibit or moderate MH15 expression or activity, thereby treating cancer, in vivo.

Claims

1. A method of detecting and diagnosing gastric cancer in a patient in need thereof, comprising the steps of:

obtaining a biological sample comprising whole blood from said patient;

analysing said biological sample for the expression of MH15 (also known as Hn1L), said analysing step comprising detecting mRNA encoded by the polynucleotide sequence set forth in SEQ ID NO;

1 in peripheral blood mononuclear cells (PBMCs) from the biological sample; and

wherein expression of said mRNA in said PBMCs at levels in excess of the level of mRNA encoded by the polynucleotide sequence set forth in SEQ ID NO;

1 in PBMCs from a normal, healthy subject indicates that said patient has gastric cancer.

4. The method according to claim 1, wherein the mRNA level of MH15 is detected by a technique selected from the group consisting of:

Northern blot;

in situ hybridization;

RNase protection;

RT-PCR based techniques;

RACE;

branched DNA technology;

nucleic acid hybridization-based techniques, and combinations thereof.

2. A method of detecting and diagnosing gastric cancer in a patient in need thereof, comprising the steps of:

(a) providing a biological sample comprising whole blood from said patient;

(b) detecting the level of MH15 (also known as Hn1L) mRNA encoded by the polynucleotide sequence set forth in SEQ ID NO;

1 in peripheral blood mononuclear cells (PBMCs) from the biological sample; and

(c) comparing the level of MH15 mRNA in the biological sample with the level of MH15 mRNA encoded by the polynucleotide sequence set forth in SEQ ID NO;

1 in a control sample of PBMCs from from a normal, healthy subject;

wherein an increased level of said MH15 mRNA in the biological sample compared to said MH15 mRNA in the control sample indicates the presence of gastric cancer in said patient.

3. The method according to claim 2, wherein said level of MH15 in said biological sample is detected by determining the mRNA level in said PBMCs with the use of a probe or primer selected from the group consisting of SEQ ID NO:

5;

SEQ ID NO;

6;

SEQ ID NO;

7 and SEQ ID NO;

8 that can hybridize with said MH15 mRNA or fragment thereof.

5. An in vitro method for monitoring the recurrence of gastric cancer in a patient who has been treated for cancer, comprising the steps of:

(a) interacting a biological sample comprising whole blood from the patient with a substance selected from polynucleotides, probes or primers that interact with MH 15 (also known as Hn1L) mRNA encoded by the polynucleotide sequence set forth in SEQ ID NO;

1;

(b) detecting the level of MH15 mRNA of SEQ ID NO;

1 that interacts with the substance in peripheral blood mononuclear cells (PBMCs) from the biological sample;

(c) repeating steps (a) and (b) using a biological sample comprising whole blood from said patient at a subsequent point of time; and

(d) comparing the level of said MH15 mRNA detected in step (c) with the level of MH15 mRNA encoded by the polynucleotide sequence set forth in SEQ ID NO;

1 detected in a control sample of PBMCs from a normal, healthy subject and therefrom determining the recurrence of gastric cancer in said patient,

wherein a level of said mRNA detected in said biological sample in step (c) in excess of the level of said MH15 mRNA detected in the control sample is indicative of a recurrence of the gastric cancer in the patient.